Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?

Autores de IIS La Fe

• Adela Cañete Nieto

  Autor

• Samuel Navarro Fos

  Autor

Participantes ajenos a IIS La Fe

• Lopez-Carrasco, Amparo
• Vieco-Marti, Isaac
• Granados-Aparici, Sofia
• Acevedo-Leon, Delia
• Estan-Capell, Nuria
• Portugal, Raquel
• Huerta-Aragones, Jorge
• Noguera, Rosa

Grupos

• Investigación Clínica y Traslacional en Cáncer

Abstract

Vitronectin is a glycoprotein present in plasma and the extracellular matrix that is implicated in cell migration. The high amount of vitronectin found in neuroblastoma biopsies has been associated with poor prognosis. Moreover, increased vitronectin levels have been described in the plasma of patients with different cancers. Our aim was to assess vitronectin as a potential circulating biomarker of neuroblastoma prognosis. Vitronectin concentration was quantified using ELISA in culture media of four neuroblastoma cell lines grown in a monolayer and in 3D models, and in the plasma of 114 neuroblastoma patients. Three of the neuroblastoma cell lines secreted vitronectin to culture media when cultured in a monolayer and 3D models. Vitronectin release was higher by neuroblastoma cells cultured in 3D models than in the monolayer and was still elevated when cells were grown in 3D scaffolds with cross-linked vitronectin. Vitronectin secretion occurred independently of cell numbers in cultures. Its concentration in the plasma of neuroblastoma patients ranged between 52.4 and 870 g/mL (median, 218 g/mL). A ROC curve was used to establish a cutoff of 361 g/mL, above which patients over 18 months old had worse prognosis (p = 0.0018). Vitronectin could be considered a new plasma prognostic biomarker in neuroblastoma and warrants confirmation in collaborative studies. Drugs inhibiting vitronectin interactions with cells and/or the extracellular matrix could represent a significant improvement in survival for neuroblastoma patients.

Keywords

• extracellular matrix; hydrogels; liquid biopsy; pediatric cancer; precision medicine